'Hazard ratio 0' presentation slideshows

If I had an acute coronary syndrome, which antiplatelet agent would I prefer?

544 views • 44 slides

Background

Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trial (ZETA). SA Wells , 1 BG Robinson, 2 RF Gagel, 3 H Dralle, 4 JA Fagin, 5 M Santoro, 6 E Baudin, 7 J Vasselli, 8 J Read 9 and M Schlumberger 7.

373 views • 15 slides

The SSC presented a data set on cervical cancer for analysis.

INTRODUCTION. The SSC presented a data set on cervical cancer for analysis. Purpose of the analysis: determine the different attributes (covariates) for predicting relapse for women that had cervical cancer and surgery, as well as classifying the patients into Low , Medium and High risk.

266 views • 15 slides

CLOTS 3

CLOTS 3. Multicentre randomised trial to evaluate Intermittent Pneumatic Compression in patients with acute stroke. Martin Dennis on behalf of The CLOTS trials collaboration. Venous thromboembolism after stroke. PE. DVT 20%. 5% symptomatic. PE 10% on screening MRI

207 views • 10 slides

Hazard ratio = 0.92 (95% CI 0.83 to 1.02) p =0.12

30. 20. 10. 0. CORONA - Primary Endpoint. The combined endpoint of cardiovascular death or non-fatal MI or non-fatal stroke (time to first event). Placebo. Rosuvastatin 10 mg. Percent of patients with primary endpoint. Hazard ratio = 0.92 (95% CI 0.83 to 1.02) p =0.12. 0. 6. 12.

236 views • 4 slides

PreCISe Primary End Point: Risk Reduction to CDMS

PreCISe Primary End Point: Risk Reduction to CDMS. Placebo. Risk Reduction of 45% Hazard Ratio= 0.55 [95% CI] 0.40-0.77 P =0.0005. GA. + 386 days: + 115%. Day 336. Day 722. Adapted from Comi G. AAN 2008, LBS.003.

101 views • 1 slides